awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q47622968-8DB98067-14CC-4B90-95F0-BB8458682272
Q47622968-8DB98067-14CC-4B90-95F0-BB8458682272
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47622968-8DB98067-14CC-4B90-95F0-BB8458682272
ATR/CHK1 inhibitors and cancer therapy.
P2860
Q47622968-8DB98067-14CC-4B90-95F0-BB8458682272
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47622968-8DB98067-14CC-4B90-95F0-BB8458682272
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
4d392ed64ff5a2ef7fe8d25f3a0d5144184b2b17
P2860
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer